PRESS RELEASE published on 05/16/2025 at 15:34, 1 year 3 months ago Form 8.3 - The Vanguard Group, Inc.: Direct Line Insurance Group plc The Vanguard Group, Inc. discloses a 5.43% stake in Direct Line Insurance Group plc. Additional disclosure on Aviva plc. Detailed Form 8.3 submission Form 8.3 Disclosure Vanguard Group Direct Line Insurance Aviva Plc
BRIEF published on 05/15/2025 at 16:10, 1 year 3 months ago Participation du groupe Vanguard dans Direct Line Insurance Groupe Vanguard Code De Prise De Contrôle Divulgation Des Enjeux Aviva Assurance Direct Line
BRIEF published on 05/15/2025 at 16:10, 1 year 3 months ago Vanguard Group's Stake in Direct Line Insurance Takeover Code Vanguard Group Stake Disclosure Direct Line Insurance Aviva
PRESS RELEASE published on 05/15/2025 at 16:05, 1 year 3 months ago Form 8.3 - The Vanguard Group, Inc.: Direct Line Insurance Group plc The Vanguard Group, Inc. discloses a 5.42% ownership in Direct Line Insurance Group plc. Purchase of ordinary shares reported Vanguard Group Ownership Disclosure Financial Disclosure Share Purchase Direct Line Insurance
BRIEF published on 05/14/2025 at 16:38, 1 year 3 months ago Vanguard Group Discloses Stake in Direct Line Insurance Securities Disclosure Takeover Code Vanguard Group Direct Line Insurance
BRIEF published on 05/14/2025 at 16:38, 1 year 3 months ago Le groupe Vanguard révèle sa participation dans Direct Line Insurance Titres Groupe Vanguard Code De Prise De Contrôle Divulgation Assurance Direct Line
PRESS RELEASE published on 05/14/2025 at 16:33, 1 year 3 months ago Form 8.3 - The Vanguard Group, Inc.: Direct Line Insurance Group plc The Vanguard Group, Inc. discloses a 5.42% ownership position in Direct Line Insurance Group plc. Additional position details revealed in Form 8.3 submission Form 8.3 The Vanguard Group Ownership Disclosure Financial Securities Direct Line Insurance Group Plc
BRIEF published on 05/12/2025 at 15:48, 1 year 3 months ago Le groupe Vanguard révèle sa participation dans Direct Line Insurance Groupe Vanguard Code De Prise De Contrôle Divulgation Des Actions Position Des Titres Assurance Direct Line
BRIEF published on 05/12/2025 at 15:48, 1 year 3 months ago Vanguard Group Discloses Stake in Direct Line Insurance Takeover Code Vanguard Group Shareholding Disclosure Direct Line Insurance Securities Position
PRESS RELEASE published on 05/12/2025 at 15:43, 1 year 3 months ago Form 8.3 - The Vanguard Group, Inc.: Direct Line Insurance Group plc The Vanguard Group, Inc. discloses a 5.42% interest in Direct Line Insurance Group plc. Purchase of 136,351 ordinary shares at 2.91 GBP per unit Vanguard Group Ownership Disclosure Financial Disclosure Securities Purchase Direct Line Insurance
Published on 09/11/2026 at 04:00, 5 hours 44 minutes ago Torq Announces Debt Settlement and Corporate Update
Published on 09/10/2026 at 22:25, 11 hours 19 minutes ago Pathfinder Ventures Announces Appointment of Mickey Perret as Chief Executive Officer
Published on 09/10/2026 at 15:20, 18 hours 24 minutes ago MicroVision to Preview Next-Generation Lidar-Based Perception Platform at IAA Transportation 2026
Published on 09/10/2026 at 15:00, 18 hours 44 minutes ago All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)
Published on 09/11/2026 at 09:20, 24 minutes ago Cantourage Expands Portfolio with New Cannabis Active Ingredients for Innovative Compounded Medicines
Published on 09/11/2026 at 09:05, 39 minutes ago ROHM's New High Anti-surge Chip Resistors in "SDR01 Series" Achieve 0.33W Rated Power in 0402 Size
Published on 09/11/2026 at 09:00, 44 minutes ago Homann Holzwerkstoffe publishes its 2026 half-year report
Published on 09/11/2026 at 07:00, 2 hours 44 minutes ago Transparantiekennisgeving van Baltisse Groep
Published on 09/11/2026 at 07:00, 2 hours 44 minutes ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 2 hours 44 minutes ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 14 hours 14 minutes ago Availability of the 2026 Interim Financial Report
